A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma

References

• Wagner AD, Syn NLX, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064.
   PubMed Web of Science ®Google Scholar
• Smyth EC, Verheij W, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(5):v38–v49.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). Gastric cancer. Version 1.2020 – March 19, 2020. [accessed on 6 May 2020].
   Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991–4997.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Tomasello G, Ghidini M, et al. Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity. Anticancer Drugs. 2017;28(2):133–141.
   PubMed Web of Science ®Google Scholar
• Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–673.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol. 2008;26(9):1435–1442.
   PubMed Web of Science ®Google Scholar
• Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol. 2008;61(4):623–629.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol (CCT). 2003;26(1):37–41.
   PubMed Web of Science ®Google Scholar
• Einzig A, Kelsen DP, Cheng E, et al. Phase II trial of carboplatin in patients with adenocarcinomas of the upper gastrointestinal tract. Cancer Treat Rep. 1985;69(12):1453–1454.
   PubMedGoogle Scholar
• Ujmajuridze Z, Ehrnrooth E, Lassen E, et al. Efficacy of carboplatin, docetaxel and capecitabine (CTX) in the treatment of patients with advanced or metastatic upper gastrointestinal tract carcinomas. A retrospective analysis. J Clin Oncol. 2008;26(15_suppl):abstr 15629.
   Web of Science ®Google Scholar
• Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38(1):143–151.
   PubMed Web of Science ®Google Scholar
• Shah MA, Janjigian YY, Stoller R, et al. Randomised multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. J Clin Oncol. 2015;33(33):3874–3879.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19(11):1882–1887.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Pauligk C, Homann N, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internististische Onkologie (FLOT65). Eur J Cancer. 2013;49(4):835–842.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Boku N, Mizusawa J, et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG 1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(7):501–510.
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Burtness BA, Niedzwiecki D, et al. CALGB 80403 (alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol. 2016;34(23):2736–2742.
   PubMed Web of Science ®Google Scholar
• Dijksterhuis WPM, Verhoeven RHA, Slingerland M, et al. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: a real-world evidence study. Int J Cancer. 2020;146(7):1889–1901.
   PubMed Web of Science ®Google Scholar
• Baumgartner R, Taghizadeh H, Jomrich G, et al. Utilization and efficacy of palliative chemotherapy for locally advanced or metastatic gastroesophageal carcinoma. Anticancer Res. 2020;40(2):965–975.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–1957.
   PubMed Web of Science ®Google Scholar